Pembrolizumab, a PD-1 inhibitor, has demonstrated robust anti-tumor activity and is commonly used as a first-line therapy in advanced CSCC, while cemiplimab, another PD-1 inhibitor, has also shown promising results, especially in patients who have not responded to previous therapies. This evidence concerns the gene PDCD1 and neoplasm.